Astrocytoma Treatment in Turkey

What Astrocytoma Is and Typical Symptoms

Astrocytoma is a primary central nervous system tumour that originates in astrocytes, the star-shaped glial cells that support and nourish nerve cells throughout the brain and spinal cord. These tumours can develop across all age groups, affecting children as well as adults. The World Health Organization classifies astrocytomas from grade 1 to grade 4 according to cellular appearance and malignancy. Grade 1 and 2 tumours, such as pilocytic astrocytoma, represent low-grade lesions that typically grow slowly. In contrast, grade 3 and 4 tumours, including anaplastic astrocytoma and glioblastoma, are high-grade, aggressive, and tend to infiltrate neighbouring healthy brain tissue.

Symptoms develop when the tumour exerts pressure on surrounding structures or impairs normal neurological signalling. Common clinical signs include:

• Persistent or morning headaches that intensify with coughing, straining, or bending over
• Unprovoked seizures, presenting as convulsive episodes or subtle focal sensory changes
• Unexplained nausea and vomiting, frequently occurring upon waking
• Noticeable behavioural, cognitive, or personality changes noted by family members
• Progressive focal neurological deficits, including limb weakness, numbness, difficulty speaking, or visual disturbances

In young children evaluated through specialised paediatrics units, symptoms may also manifest as head enlargement, persistent irritability, developmental regression, or new motor coordination difficulties.

How Astrocytoma Is Diagnosed and Records to Bring

Accurate diagnosis and grading require comprehensive neurological evaluation, high-resolution imaging, and histopathological analysis. When visiting a hospital in Turkey, diagnostic procedures arranged through check-ups and diagnostics departments typically include:

• Magnetic Resonance Imaging (MRI): Detailed contrast-enhanced brain MRI, often supplemented by advanced sequences such as MR spectroscopy, diffusion tensor imaging, and functional MRI to map speech and motor areas.
• Computed Tomography (CT) Scans: Useful for evaluating acute intracranial haemorrhage, calcification, or associated bone involvement.
• Stereotactic Biopsy or Surgical Tissue Sampling: Examination of tumour tissue under a microscope remains the definitive method to determine cellular grade.
• Advanced Molecular and Genetic Testing: Assessment of IDH1 and IDH2 mutation status, 1p/19q codeletion, ATRX expression, and MGMT promoter methylation to direct therapy.

Patients travelling from abroad must bring all available historical medical documentation. This includes original DICOM imaging files of past MRI and CT scans on CD or flash drive, formal radiology summaries, prior pathology reports with physical biopsy slides or tissue blocks if available, recent laboratory blood results, and a complete list of current prescription medicines.

Treatment Options and When Each Is Used

Treatment choices depend on the tumour grade, anatomical location, molecular characteristics, and the overall functional status of the patient. Multidisciplinary teams collaborate to establish an individualised management strategy combining surgery, radiation, and medication.

Following surgical resection or radiation, structured neurological rehabilitation plays an important role in helping patients regain motor skills, speech clarity, and cognitive endurance during recovery.

Planning Treatment in Turkey and Post-Care at Home

The journey begins with an initial remote case review. Specialist teams review previous imaging, medical summaries, and pathology reports to assess treatment suitability and outline an expected clinical schedule before the patient travels.

The duration of stay varies according to the treatment plan. Initial diagnostic consultations and repeating imaging generally require 4 to 7 days. If neurosurgical resection is undertaken, patients usually remain in Turkey for 2 to 3 weeks to complete pre-operative preparation, surgery, in-hospital recovery, and suture removal before being cleared to fly. If a full course of radiotherapy is administered, the stay may extend to 6 weeks.

Upon discharge, the hospital provides translated medical summaries, operative notes, and post-procedure imaging files. Continuing care must be pre-arranged with an oncologist or neurologist in your home country to coordinate periodic MRI surveillance, blood work, and long-term symptom management.

When Travel Is Not Advisable and Urgent Warning Signs

Air travel involves changes in atmospheric cabin pressure that can aggravate intracranial swelling or provoke seizures in unstable patients. Travel is not advisable if a patient has severe uncontrolled intracranial pressure, active cerebral oedema, or unmanaged seizures. Furthermore, flying is contraindicated immediately after craniotomy until trapped intracranial air has fully resolved.

Do not attempt international travel if any of the following urgent warning signs appear; seek emergency medical care locally instead:

• Sudden and intense headaches that fail to subside with prescribed medication
• Repeated, projectile vomiting accompanied by increasing drowsiness or confusion
• New or rapidly progressing motor weakness affecting the face, arm, or leg
• Prolonged seizures or multiple convulsions occurring without recovery in between
• Sudden deterioration in vision, double vision, or unequal pupil size

All treatment decisions are determined by the treating doctor following an in-person clinical assessment and comprehensive diagnostic review.